Filing summary
Entity and period: The supplied filing is Lianluo Smart Limited’s Form 20-F for the fiscal year ended December 31, 2016, not a Newegg Commerce, Inc. filing or a quarterly report for 2016 Q4. Newegg appears only in a director’s biography, which says Lianluo Interactive acquired the retailer. The financial statements are audited and prepared under U.S. GAAP; 2014 figures are marked restated.
Business context and reporting period
Lianluo Smart, formerly Dehaier Medical Systems Limited, changed its name and Nasdaq ticker to LLIT in November 2016. It shifted away from traditional medical-device lines toward mobile health, particularly wearable sleep-apnea diagnosis and sleep-respiratory products, while retaining selected medical-device businesses. Its operations are primarily in China. On July 31, 2016, it terminated its VIE agreement with Beijing Dehaier Technology Limited (BTL) and deconsolidated BTL; related results are reported as discontinued operations.
The filing reports annual results through December 31, 2016. It does not provide a clear standalone fourth-quarter income statement or Q4-specific operating metrics.
Financial performance and position
| Metric (US$ unless noted) | FY2016 | FY2015 |
|---|---|---|
| Continuing-operations revenue | $13.06 million | $0.74 million |
| Gross profit (loss) | $(3.57) million | $(0.19) million |
| Gross margin | (27%) | (26%) |
| Operating loss | $(9.08) million | $(6.90) million |
| Net loss | $(10.25) million | $(10.36) million |
| Net loss attributable to Lianluo Smart | $(10.12) million | $(10.22) million |
| Basic loss per share | $(0.97) | $(1.74) |
| Cash and cash equivalents at year-end | $10.79 million | $0.62 million |
| Working capital at year-end | $10.22 million | $0.46 million |
| Total current liabilities at year-end | $1.12 million | $6.41 million |
| Short-term borrowings at year-end | Nil | $3.72 million, including related-party borrowings |
| Net cash used in operating activities | $(2.76) million | $(2.34) million |
| Net cash used in investing activities | $(0.65) million | $(0.03) million |
| Net cash provided by financing activities | $13.68 million | $1.50 million |
Revenue grew 1,669% year over year, principally from sleep-respiratory/mobile-medicine products and a new customer relationship with Hongyuan. Management said portable sleep-diagnostic devices represented about 90% of 2016 sales. The filing reports that the company’s three largest products accounted for approximately 97% of total net revenue.
Despite the revenue increase, cost of revenue exceeded sales. Management attributed the larger gross loss primarily to a lower-margin market-entry strategy, higher fixed costs allocated to remaining product lines, and inventory write-downs/disposals. The filing identifies approximately $2.45 million of 2016 inventory obsolescence provision and reports depreciation and amortization of $1.23 million, up from $0.53 million in 2015; shortened estimated useful lives for certain equipment contributed to the increase.
Operating cash outflow increased to $2.76 million. The company’s cash position was boosted by financing, chiefly the 2016 share issuance to Hangzhou Lianluo Interactive Information Technology Co., Ltd. (HLI). The filing records $18.41 million of net proceeds from issuing 11,111,111 shares and warrants, and a $1.49 million subscription receivable at year-end, collected in April 2017. The company repaid its bank borrowings and related-party loans during 2016; it reported no year-end short-term borrowings.
Material changes, outlook, and risks
- Strategic restructuring: The company discontinued or scaled back several traditional medical-device lines and focused resources on sleep-respiratory and mobile-health products. Discontinued-operations loss fell to $0.25 million from $3.66 million in 2015; continuing-operations loss increased to $10.00 million from $6.70 million.
- Capital and dilution: HLI’s $20 million share-and-warrant transaction substantially increased shares outstanding. At December 31, 2016, 17,312,586 common shares were outstanding; HLI also received warrants to purchase 1,000,000 shares at $2.20 per share.
- Management outlook: Management expected sleep-respiratory business to drive significant revenue growth in 2017 and described expansion through hospitals, examination centers, distributors, and potential insurance partnerships. This is an expectation, not quantified guidance; the filing gives no specific revenue, margin, or earnings forecast.
- Customer and supplier concentration: Two customers accounted for approximately 94% of continuing-operations revenue in 2016, and three suppliers accounted for approximately 98% of continuing-operations purchases. The company also relies heavily on distributors.
- Execution and product risks: The new business was described as early-stage, with negative gross margins. Risks include market acceptance, price competition, product obsolescence, regulatory approvals and renewals, supply continuity, distributor conduct, and dependence on a small number of products and key personnel.
- China-related risks: The filing describes foreign-exchange and remittance restrictions, regulatory and legal uncertainty, potential tax exposure, and risks from operating primarily in China. The company said it did not hedge currency exposure.
- Controls and audit history: Management concluded disclosure controls and procedures were ineffective as of year-end. It also described manual inventory-management processes and plans to implement and train staff on an ERP system. Separately, management said it did not identify significant deficiencies or material weaknesses in internal control over financial reporting, while acknowledging inventory-process errors could occur and reduce efficiency. The auditor issued an unqualified opinion on the financial statements but did not audit internal-control effectiveness. The prior auditor had said it lacked sufficient information to complete the 2015 audit and raised questions about evidence for certain receivable, inventory, prepayment, and other-receivable write-offs and reserves.
- Other items: The company recorded a $1.09 million loss on warrant redemption and paid $1.12 million to repurchase warrants. It reported no significant pending or contemplated legal proceedings and no cash dividends paid or expected in the foreseeable future.
Most important facts to verify
- Confirm the filing identity and period: this is Lianluo Smart’s FY2016 Form 20-F, not Newegg’s filing or a standalone Q4 report.
- Reconcile the HLI share transaction, warrants, proceeds, and ownership disclosures. The filing gives inconsistent share counts or ownership presentation in places, including 11,111,111 shares in the transaction disclosure and a major-shareholder table that also shows 64.18% ownership.
- Assess whether the 2016 revenue increase is repeatable given customer concentration, the Hongyuan relationship, negative gross margin, and reliance on sleep-diagnostic products.
- Review the $2.45 million inventory obsolescence charge, inventory balances, and planned inventory-control remediation, especially given management’s disclosure-controls conclusion and the prior auditor’s information concerns.
- Confirm the timing and financial effect of the VIE termination and BTL deconsolidation, including which historical results and balances are classified as discontinued operations.
- Track whether the company achieved its 2017 growth expectations and improved gross margins; the filing supplies no quantified guidance against which to measure progress.